Filing Flows › Cytokinetics (CYTK) › Q3 2026 › vs Q3 2025
Cytokinetics (CYTK) Q3 2026 vs Q3 2025 (year over year)
Cytokinetics's revenue rose $45.6M (25×) from $1.9M in Q3 2025 to $47.6M in Q3 2026. The biggest changes: Net Product Revenue +$44.5M (—); Collaboration Revenues +$1.1M (+58%).
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Net Product Revenue | $44.5M | $0 | $44.5M | — |
| Collaboration Revenues | $3.0M | $1.9M | $1.1M | +58% |
| Revenue | $47.6M | $1.9M | $45.6M | 25× |
| Net loss | $190M | $306M | −$116M | -38% |
| Costs & expenses | $238M | $308M | −$70.5M | -23% |
| Operating costs | $215M | $169M | $46.0M | +27% |
| Interest & other, net | $23.0M | $139M | −$116M | -84% |
| Research & development | $99.3M | $97.3M | $2.0M | +2% |
| SG&A | $113M | $69.5M | $43.7M | +63% |
| Other operating costs | $2.2M | $1.9M | $280K | +14% |
| Operating cash sources | $190M | $306M | −$116M | -38% |
| Depreciation & amortization | $3.6M | $2.7M | $969K | +36% |
| Share-based compensation | $34.7M | $30.7M | $4.0M | +13% |
| Working capital & other | $27.7M | $165M | −$138M | -83% |
| Cash used in operations | $124M | $108M | $16.5M | +15% |
| Net loss absorbed | $190M | $306M | −$116M | -38% |
Questions
How much did Cytokinetics's revenue grow year over year in Q3 2026?
Cytokinetics's revenue rose $45.6M (25×) from $1.9M in Q3 2025 to $47.6M in Q3 2026.
What drove Cytokinetics's revenue change in Q3 2026?
Net Product Revenue +$44.5M (—); Collaboration Revenues +$1.1M (+58%).